TABLE 1.
Characteristics of patients and HIV-1 DNA levels in purified resting CD4+ T lymphocytes
| Patient no. | Drug regimena | Plasma HIV-1 RNA level at time of analysis (no. of copies/ml) | Duration of virologic suppression (mo) | HIV-1 DNA level (no. of copies/ 106 resting CD4+ T cells) |
|---|---|---|---|---|
| 1 | AZT/3TC/NFV | <50 | 30 | 20 |
| 2 | AZT/ddC/NVP | <50 | 58 | 100 |
| 3 | 3TC/d4T/RTV | <50 | 54 | 60 |
| 4b | AZT/3TC/EFV/ABC | <50 | 48 | 100 |
| <50 | 50 | 120 | ||
| 5 | 3TC/EFV/ABC | <50 | 23 | 120 |
| 6 | AZT/3TC/IDV/RTV | <50 | 45 | 50 |
| 7 | AZT/3TC/EFV | <50 | 45 | 50 |
| 8 | 3TC/d4T/NFV | 125 | 32 | 1,000 |
| 9 | 3TC/d4T/NFV | <50 | 51 | 120 |
| Median | <50 | 47 | 100 |
a
Abbreviations for antiretroviral drugs: AZT, zidovudine; 3TC, lamivudine; ddC, zalcitabine; d4T, stavudine; ABC, abacavir; NVP, nevirapine; EFV, efavirenz; IDV, indinavir; RTV, ritonavir; NFV, nelfinavir.
b
Analysis of HIV-1 DNA from T lymphocytes from patient 4 was performed on two separate occasions.